Chen Xianyu, He Chao, Han Dongdong, Zhou Meirong, Wang Quan, Tian Jinhui, Li Lun, Xu Feng, Zhou Enxiang, Yang Kehu
Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Department of Urology, the Second Hospital of Lanzhou University, Lanzhou, China.
Future Oncol. 2017 Apr;13(9):843-857. doi: 10.2217/fon-2016-0420. Epub 2017 Jan 11.
To review the predictive values of Ki-67 before neoadjuvant chemotherapy (NAC) for breast cancer patients.
PubMed and EMBASE were searched. Random-effect model meta-analysis was conducted using Revman software.
High Ki-67 was associated with more pathological complete responses (pCRs) events (odds ratio: 3.10; 95% CI: 2.52-3.81; 53 studies, 10,848 patients) regardless of HR, HER2 and triple-negative breast cancer types, the definitions of pCR and cut-off points for Ki-67. Ki-67 could predict pCR in those who received anthracyclines plus taxanes, and anthracyclines only, and those from Asia and Europe.
High Ki-67 before NAC was a predictor for pCR in neoadjuvant setting for breast cancer patients.
回顾新辅助化疗（NAC）前Ki-67对乳腺癌患者的预测价值。
检索PubMed和EMBASE。使用Revman软件进行随机效应模型荟萃分析。
无论HR、HER2和三阴性乳腺癌类型、pCR的定义以及Ki-67的切点如何，高Ki-67与更多的病理完全缓解（pCR）事件相关（优势比：3.10；95%可信区间：2.52 - 3.81；53项研究，10848例患者）。Ki-67可以预测接受蒽环类药物加紫杉类药物、仅接受蒽环类药物治疗的患者以及来自亚洲和欧洲的患者的pCR。
NAC前高Ki-67是乳腺癌患者新辅助治疗中pCR的预测指标。
